Which Cannabis Stock Makes the Better Buy: Aurora Cannabis (TSX:ACB) or Canopy Growth (TSX:WEED)?

Here’s a closer look at Canada’s two most popular cannabis stocks, Canopy Growth (TSX:WEED)(NYSE:CGC) and Aurora Cannabis (TSX:ACB)(NYSE:ACB), to determine which one is the better buy.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canada’s two largest (and most popular) cannabis stocks thus far have been Canopy Growth (TSX:WEED)(NYSE:CGC) and Aurora Cannabis (TSX:ACB)(NYSE:ACB).

But among the two, which one is the better buy? Let’s take a closer look and try to figure this out.

Size advantage

On the surface, you would think that Canopy Growth would get the nod here, but it’s actually not quite that simple.

Canopy has a market capitalization just shy of $18 billion, which is far larger than Aurora’s market cap of a little less than $10 billion, but if we look at the potential capacity of their available production facilities, the picture begins to get a little fuzzier.

Aurora claims in its latest reporting that it has up to 625,000 kg of annual production that’s already been funded.

Canopy, meanwhile, claims that it has over five million square feet of available production space.

When you look at the numbers closer, there’s not a whole lot to differentiate the two in terms of how much they should be able to produce at full capacity.

Whether the two companies will be able to secure distribution for all that product is a different story entirely, but for now, I’m calling this one a draw.

The international opportunity

One thing continues to become clear about cannabis markets, and that is, rather than being strictly a Canadian or “domestic” play, the cannabis industry continues to appear more and more as though it will inevitably become “global” in nature.

In this respect, I’m going to go ahead and give Canopy the edge.

Not only has it already managed to partner with a mega-player in $35 billion market cap alcohol and spirits distributor Constellation Brands, but it’s also already got operations in 15 different countries, including what it hopes will be a first-mover advantage in the potentially massive U.S. market.

Aurora too, is already active internationally, including operations in more than 24 countries, but it’s also made significant investments in positioning itself as a vertically integrated domestic supplier, including most notably its investment in Alcanna last year.

With the potential size of the global market for cannabis products estimated at nearly 10 times the size of the Canadian market, I have to wonder if ACB might have already spread itself too thin to be able to appropriately attack any attractive international opportunities should they arise.

A strategic partner

In my own opinion, Canopy’s $4 billion partnership with the aforementioned Constellation Brands could end up making a significant impact on its ability to successfully tap into not only markets outside Canada but into adjacent product categories.

Working alongside a mega-partner like Constellation, Canopy should have the leg up when it comes to a sales team that can help it secure international distribution, technology that can enable it to advance the cultivation and extraction process, and a unique opportunity to partner on exciting new projects like cannabis-infused adult beverages.

Foolish bottom line

I happen to like the outlook for both of these companies, but in terms of the one that’s created the most clear vision of a future that happens to be aligned with my own outlook, I’m going to have to go ahead and give the nod to Canopy here, which is slightly ahead of Aurora Cannabis.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jason Phillips has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »